Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-05

Study Completion Date

2019-06-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study evaluates the effect of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head in comparison to the standard treatment of isolated core decompression.

XCEL-MT-OSTEO-ALPHA is a tissue engineering product composed by "ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue.

The working hypothesis proposes that the tissue engineering is a valid and useful technique to achieve bone regeneration, avoiding the progression to collapse of the femoral head.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells

NCT01700920

Osteonecrosis of the Femoral Head

COMPLETED PHASE2

Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip

NCT02065167

Avascular Necrosis of the Femoral Head

COMPLETED PHASE2

Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head

NCT00813267

Osteochondritis of the Femoral Head

UNKNOWN EARLY_PHASE1

The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)

NCT03180463

Osteonecrosis of Femoral Head

SUSPENDED PHASE1/PHASE2

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

NCT00505219

Osteonecrosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, open-label with blinded assessor, randomized, parallel, single-dose phase I-II clinical trial in which 24 patients affected with osteonecrosis of the femoral head ARCO grade I or II will enter the trial with the primary objective of assessing the feasibility and safety of "ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in osteonecrosis of the femoral head. Secondary objectives are to assess the efficacy of the implantation by imaging (magnetic resonance imaging) and clinical questionnaires (pain by visual analogue scale, quality of life by SF-36 and WOMAC Index).

Patients will be randomized to one of the two treatment arms (core decompression and the tissue engineering product composed by "ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue or the standard treatment of isolated core decompression). Thereafter, patients will be followed for 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Avascular Necrosis of Femur Head

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

XCEL-MT-OSTEO-ALPHA

"ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head

Group Type EXPERIMENTAL

XCEL-MT-OSTEO-ALPHA

Intervention Type BIOLOGICAL

Core decompression plus XCEL-MT-OSTEO-ALPHA

Standard Treatment

Isolated core decompression

Group Type SHAM_COMPARATOR

Standard treatment

Intervention Type PROCEDURE

Isolated core decompression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XCEL-MT-OSTEO-ALPHA

Core decompression plus XCEL-MT-OSTEO-ALPHA

Intervention Type BIOLOGICAL

Standard treatment

Isolated core decompression

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 50 years of age (male and female)
* Osteonecrosis of the hip ARCO grade I or II
* Abscence of systemic or local infection
* Laboratory tests with no relevant abnormal findings that contraindicate the surgery.
* Informed Consent Form signed
* The patient is able to understand the nature of the study

Exclusion Criteria

* Osteonecrosis of the hip secondary to femoral neck fracture
* Patients with no closed cartilage
* Surgical implants in the femoral head
* Septic arthritis
* Patients with severe renal insufficiency
* Patients expecting or with liver transplantation
* Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) or Syphilis.
* Pregnant woman or intended to become pregnant, or breath feeding
* Neoplasia within the previous 5 years, or without remission
* Immunosuppressive states
* The patient is legally dependent
* Participation in another clinical trial or treated with an investigational medicinal product the previous 30 days
* Cardiac pacemaker, allergy to contrast or any other condition that contraindicates the MRI with contrast agents
* Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria
* The patient does not accept to be followed-up for a period thar could exceed the clinical trial length

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No